




The relative strengths and weaknesses of Keros Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Keros Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 440%, being 211% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	315,434
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,414
Liabilities, Non-Current	14,475
Other Assets	18,290
Other Compr. Net Income	0
Other Expenses	4,883
Other Liabilities	0
Other Net Income	24,328
Other Revenues	244,061
Property and Equipment	4,297
Research and Development	129,643
Selling, General and Administrative Expense	46,849

Output Variable	Value in 1000 USD
Assets	338,021
Liabilities	34,889
Expenses	181,375
Revenues	244,061
Stockholders Equity	303,132
Net Income	87,014
Comprehensive Net Income	87,014
BaseVar	411,337
ECR before Limited Liability	401%
Economic Capital Ratio	440%